Advances in pharmacotherapy for pediatric anxiety disorders
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Pediatric anxiety disorders are prevalent, chronic, and often lead to significant impaired functioning that impacts both short- and long-term outcomes for children and adolescents. Treatment options include pharmacotherapy and psychosocial interventions. This presentation will review treatment advances specifically for pharmacotherapy. Current research supports serotonin reuptake inhibitors as the medication class to be the first-line treatment option for pediatric anxiety disorders. Available evidence for the efficacy of other classes of medications will be reviewed, along with the available approaches to manage partial responders and nonresponders. The risks and benefits of pharmacotherapy will also be reviewed. In addition, recent research has shown the potential promise of novel agents that act upon other neural systems implicated in the development of pediatric anxiety disorders. Novel compounds that affect the glutamate system will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 1×
“[10] Childhood anxiety disorders often lead to difficulties in adolescence and adulthood, such as anxiety and depressive disorders,[11] substance abuse and dependence,[12] and suicidal behavior.”
BackgroundPine, D. S., Cohen, P., Gurley, D., Brook, J., & Ma, Y. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.56 · Cited by 1,753
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Self-citationβ-Adrenergic activation and memory for emotional events
Cahill, L., Prins, B., Weber, M., & McGaugh, J. L. (1994) · Nature · doi:10.1038/371702a0 · Cited by 1,271
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 1×
“Double-blinded clinical trials have demonstrated that exposure therapy augmented by DCS was superior to exposure therapy augmented by placebo in the treatment of specific phobia of heights,[47] social phobia,[48,49] and panic disorder.”
BackgroundFoa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Pilot study of secondary prevention of posttraumatic stress disorder with propranolol
Pitman, R. K., Sanders, K. M., Zusman, R. M., Healy, A. R., Cheema, F., Lasko, N. B., Cahill, L., & Orr, S. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01279-3 · Cited by 964
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Comorbidity of anxiety and depression in children and adolescents
Brady, E. U., & Kendall, P. C. (1992) · Psychological Bulletin · doi:10.1037/0033-2909.111.2.244 · Cited by 748
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 1×
“Double-blinded clinical trials have demonstrated that exposure therapy augmented by DCS was superior to exposure therapy augmented by placebo in the treatment of specific phobia of heights,[47] social phobia,[48,49] and panic disorder.”
BackgroundBrunet, A., Orr, S. P., Tremblay, J., Robertson, K., Nader, K., & Pitman, R. K. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.006 · Cited by 548 · cited 1×
“Case studies,[87,88] analog studies,[89] and open trials[90] have also suggested that propanolol may treat PTSD and possibly prevent its onset.”
BackgroundA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 2×
“[54] A recent meta-analysis by Norberg et al.[55] suggested several factors that may impact the efficacy of DCS as an adjunct to CBT.”
MethodImmediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma
Vaiva, G., Ducrocq, F., Jezequel, K., Averland, B., Lestavel, P., Brunet, A., & Marmar, C. R. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00412-8 · Cited by 499 · cited 1×
“Case studies,[87,88] analog studies,[89] and open trials[90] have also suggested that propanolol may treat PTSD and possibly prevent its onset.”
BackgroundEffects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498
Marks, I. M., Swinson, R. P., Başoǧlu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P. T., Kirby, M., McNamee, G., Sengun, S., et al. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.6.776 · Cited by 478 · cited 1×
“[18] Recent large-scale trials for social phobia and OCD did not demonstrate long-term benefit of adding antidepressant medications to exposure-based therapy;[41,42] similar findings were obtained for studies that intend to augment exposure-based therapy with benzodiazepines.[43] Certainly, there have been major advan…”
ResultFluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · cited 1×
“[18] Recent large-scale trials for social phobia and OCD did not demonstrate long-term benefit of adding antidepressant medications to exposure-based therapy;[41,42] similar findings were obtained for studies that intend to augment exposure-based therapy with benzodiazepines.”
ResultEffects of D-cycloserine on extinction of conditioned freezing.
Ledgerwood, L., Richardson, R., & Cranney, J. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.2.341 · Cited by 388
Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050776 · Cited by 358 · cited 3×
“[50] Moreover, two studies, examining the additive effects to exposure and response prevention for OCD in adults, found that the DCS and placebo groups did not differ in OCD severity at posttreatment, but the DCS group exhibited gains more quickly during treatment than did the placebo group.[51,52] Other studies have…”
BackgroundResultGuastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326 · cited 1×
“Double-blinded clinical trials have demonstrated that exposure therapy augmented by DCS was superior to exposure therapy augmented by placebo in the treatment of specific phobia of heights,[47] social phobia,[48,49] and panic disorder.”
BackgroundRiluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 2×
“[65] Elevations in transaminases were reported for some participants in three studies,[65,66,71] but none of these elevations led to discontinuation of Riluzole.”
BackgroundResultSchool Refusal in Children and Adolescents: A Review of the Past 10 Years
KING, N. J., & BERNSTEIN, G. A. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00014 · Cited by 310 · cited 1×
“[29–32] These inconsistencies are likely caused by different diagnoses/comorbidities, varying medication dosages, small sample sizes, and the inclusion of participants in additional nonstandardized psychotherapies.[33] Gittelman-Klein and Klein found that medication (imipramine) was significantly better for treating s…”
BackgroundCOHEN, J. A., MANNARINO, A. P., PEREL, J. M., & STARON, V. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180547105 · Cited by 300 · cited 1×
“the effects of trauma-focused CBT (tf-CBT) combined with sertraline were compared with tf-CBT plus placebo.[19] Participants consisted of 24 children, ages 10–17 years, who were experiencing PTSD (92%) or Posttraumatic Stress Syndrome.”
MethodEfficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240 · cited 2×
“[16] found that treatment of pediatric social phobia with paroxetine led to higher response rates than placebo (78% with medication group versus 38% with placebo) (see Table 1).[16] Adverse events (e.”
BackgroundSET-C Versus Fluoxetine in the Treatment of Childhood Social Phobia
BEIDEL, D. C., TURNER, S. M., SALLEE, F. R., AMMERMAN, R. T., CROSBY, L. A., & PATHAK, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318154bb57 · Cited by 223
Imipramine Plus Cognitive-Behavioral Therapy in the Treatment of School Refusal
BERNSTEIN, G. A., BORCHARDT, C. M., PERWIEN, A. R., CROSBY, R. D., KUSHNER, M. G., THURAS, P. D., & LAST, C. G. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200003000-00008 · Cited by 216 · cited 1×
“compared CBT plus imipramine to placebo plus CBT for school refusal.[38] They focused on adolescents with comorbid anxiety and depressive disorders, and found that at posttreatment, the imipramine plus CBT group’s weekly attendance was significantly more improved (70 versus 28% of the time, Po.”
BackgroundImipramine Treatment of Children with Separation Anxiety Disorder
KLEIN, R. G., KOPLEWICZ, H. S., & KANNER, A. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00005 · Cited by 201 · cited 4×
“[34] However, Klein et al. also compared imipramine to placebo for children with a primary diagnosis of separation anxiety disorder (71% with school refusal) and failed to find differences between groups (see Table 1).”
BackgroundInfluentialD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200 · cited 1×
“[51,52] Other studies have found that the augmentation of CBT did not lead to greater treatment gains than CBT by itself or augmented with a placebo in the treatment of OCD[53] or spider fear.”
Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197
Challenges in Developing Novel Treatments for Childhood Disorders: Lessons from Research on Anxiety
Pine, D. S., Helfinstein, S. M., Bar-Haim, Y., Nelson, E., & Fox, N. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.113 · Cited by 194
fMRI predictors of treatment outcome in pediatric anxiety disorders
McClure, E. B., Adler, A., Monk, C. S., Cameron, J., Smith, S., Nelson, E. E., Leibenluft, E., Ernst, M., & Pine, D. S. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0542-9 · Cited by 165 · cited 1×
“An example of this is the finding that greater activity in the left amygdala predicts medication response.[99] As the fields of clinical therapeutics and biological research continue to integrate to pursue these lines of inquiry, there is hope for continued advancement for the development of targeted treatments for th…”
BackgroundA randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear
Guastella, A. J., Dadds, M. R., Lovibond, P. F., Mitchell, P., & Richardson, R. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.006 · Cited by 164
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
A Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder
March, J. S., Entusah, A. R., Rynn, M., Albano, A. M., & Tourian, K. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.025 · Cited by 156 · cited 1×
“examined the efficacy of venlafaxine ER in the treatment of social phobia.[17] The study found that participants receiving venlafaxine had a greater reduction in their social anxiety symptoms compared to placebo (response rates in the two groups were 56 versus 37%, respectively) (see Table 1).”
BackgroundSelf-citationGuastella, A. J., Lovibond, P. F., Dadds, M. R., Mitchell, P., & Richardson, R. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2006.07.005 · Cited by 106 · cited 1×
“This argument is supported by the failure of DCS to improve the efficacy of exposure treatment in subclinical spider-fearing individuals[54] or in individuals trained to exhibit a fear response.[56] Second, they argued that DCS is most efficacious when administered immediately before or after exposure therapy.”
BackgroundPine, D. S. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602760386888 · Cited by 73
Memantine as an Augmenting Agent for Severe Pediatric OCD
HEZEL, D. M., BEATTIE, K., & STEWART, S. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091427 · Cited by 55
Cited by
Strawn, J. R., Compton, S. N., Robertson, B., Albano, A. M., Hamdani, M., & Rynn, M. A. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0132 · Cited by 55
Self-citationAn update on Posttraumatic Stress Disorder in children and adolescents
Connor, D. F., Ford, J. D., Arnsten, A. F. T., & Greene, C. A. (2015) · Clinical Pediatrics · doi:10.1177/0009922814540793 · Cited by 46
Levy, H. C., Stevens, K. T., & Tolin, D. F. (2022) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13486 · Cited by 36
da Costa, C. Z. G., de Morais, R. M. C. B., Zanetta, D. M. T., Turkiewicz, G., Neto, F. L., Morikawa, M., Rodrigues, C. L., Labbadia, E. M., & Asbahr, F. R. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0110 · Cited by 31
The risks versus the benefits of pharmacological intervention in social anxiety disorder in children
Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461763 · Cited by 2
Metadata
- Authors
- Rynn, M., Puliafico, A., Heleniak, C., Rikhi, P., Ghalib, K., & Vidair, H.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 28
- Issue
- 1
- Pages
- 76-87
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2092166772
- Cited by
- 44
- References
- 38
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.